vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
TRANSACT TECHNOLOGIES INC is the larger business by last-quarter revenue ($11.5M vs $9.1M, roughly 1.3× Protalix BioTherapeutics, Inc.). On growth, TRANSACT TECHNOLOGIES INC posted the faster year-over-year revenue change (11.9% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $589.0K). Over the past eight quarters, TRANSACT TECHNOLOGIES INC's revenue compounded faster (3.5% CAGR vs -6.7%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
PLX vs TACT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $11.5M |
| Net Profit | $-5.5M | — |
| Gross Margin | 49.4% | 47.6% |
| Operating Margin | -51.1% | -10.1% |
| Net Margin | -60.3% | — |
| Revenue YoY | -49.9% | 11.9% |
| Net Profit YoY | -184.8% | — |
| EPS (diluted) | $-0.06 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $11.5M | ||
| Q3 25 | $17.9M | $13.2M | ||
| Q2 25 | $15.7M | $13.8M | ||
| Q1 25 | $10.1M | $13.1M | ||
| Q4 24 | $18.2M | $10.2M | ||
| Q3 24 | $18.0M | $10.9M | ||
| Q2 24 | $13.5M | $11.6M | ||
| Q1 24 | — | $10.7M |
| Q4 25 | $-5.5M | — | ||
| Q3 25 | $2.4M | $15.0K | ||
| Q2 25 | $164.0K | $-143.0K | ||
| Q1 25 | $-3.6M | $19.0K | ||
| Q4 24 | $6.5M | — | ||
| Q3 24 | $3.2M | $-551.0K | ||
| Q2 24 | $-2.2M | $-319.0K | ||
| Q1 24 | — | $-1.0M |
| Q4 25 | 49.4% | 47.6% | ||
| Q3 25 | 53.4% | 49.8% | ||
| Q2 25 | 62.5% | 48.2% | ||
| Q1 25 | 19.1% | 48.7% | ||
| Q4 24 | 78.7% | 44.2% | ||
| Q3 24 | 53.4% | 48.1% | ||
| Q2 24 | 29.8% | 52.7% | ||
| Q1 24 | — | 52.6% |
| Q4 25 | -51.1% | -10.1% | ||
| Q3 25 | 11.9% | 0.1% | ||
| Q2 25 | 7.5% | -1.9% | ||
| Q1 25 | -41.0% | -0.1% | ||
| Q4 24 | 39.6% | -10.3% | ||
| Q3 24 | 22.2% | -7.7% | ||
| Q2 24 | -18.0% | -3.8% | ||
| Q1 24 | — | -12.2% |
| Q4 25 | -60.3% | — | ||
| Q3 25 | 13.2% | 0.1% | ||
| Q2 25 | 1.0% | -1.0% | ||
| Q1 25 | -35.8% | 0.1% | ||
| Q4 24 | 35.6% | — | ||
| Q3 24 | 18.0% | -5.1% | ||
| Q2 24 | -16.4% | -2.8% | ||
| Q1 24 | — | -9.7% |
| Q4 25 | $-0.06 | $-0.11 | ||
| Q3 25 | $0.03 | $0.00 | ||
| Q2 25 | $0.00 | $-0.01 | ||
| Q1 25 | $-0.05 | $0.00 | ||
| Q4 24 | $0.10 | $-0.80 | ||
| Q3 24 | $0.03 | $-0.06 | ||
| Q2 24 | $-0.03 | $-0.03 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.2M | $31.1M |
| Total Assets | $82.3M | $44.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $20.4M | ||
| Q3 25 | $13.6M | $20.0M | ||
| Q2 25 | $17.9M | $17.7M | ||
| Q1 25 | $19.5M | $14.2M | ||
| Q4 24 | $19.8M | $14.4M | ||
| Q3 24 | $27.4M | $11.3M | ||
| Q2 24 | $23.4M | $11.1M | ||
| Q1 24 | — | $10.6M |
| Q4 25 | $48.2M | $31.1M | ||
| Q3 25 | $52.9M | $31.8M | ||
| Q2 25 | $49.9M | $31.3M | ||
| Q1 25 | $45.2M | $30.9M | ||
| Q4 24 | $43.2M | $30.6M | ||
| Q3 24 | $32.4M | $38.4M | ||
| Q2 24 | $28.6M | $38.5M | ||
| Q1 24 | — | $38.6M |
| Q4 25 | $82.3M | $44.8M | ||
| Q3 25 | $82.3M | $45.0M | ||
| Q2 25 | $78.5M | $44.5M | ||
| Q1 25 | $73.9M | $44.2M | ||
| Q4 24 | $73.4M | $44.0M | ||
| Q3 24 | $61.6M | $50.5M | ||
| Q2 24 | $91.5M | $50.4M | ||
| Q1 24 | — | $51.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $609.0K |
| Free Cash FlowOCF − Capex | $1.6M | $589.0K |
| FCF MarginFCF / Revenue | 17.8% | 5.1% |
| Capex IntensityCapex / Revenue | 4.4% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $609.0K | ||
| Q3 25 | $-3.7M | $3.6M | ||
| Q2 25 | $-5.2M | $3.6M | ||
| Q1 25 | $-5.1M | $-161.0K | ||
| Q4 24 | $4.0M | $2.4M | ||
| Q3 24 | $4.1M | $327.0K | ||
| Q2 24 | $-3.6M | $636.0K | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | $1.6M | $589.0K | ||
| Q3 25 | $-4.2M | $3.6M | ||
| Q2 25 | $-5.7M | $3.6M | ||
| Q1 25 | $-5.4M | $-171.0K | ||
| Q4 24 | $3.6M | $2.4M | ||
| Q3 24 | $4.0M | $259.0K | ||
| Q2 24 | $-3.8M | $499.0K | ||
| Q1 24 | — | $-1.6M |
| Q4 25 | 17.8% | 5.1% | ||
| Q3 25 | -23.7% | 27.1% | ||
| Q2 25 | -36.2% | 25.9% | ||
| Q1 25 | -53.0% | -1.3% | ||
| Q4 24 | 19.6% | 23.2% | ||
| Q3 24 | 22.4% | 2.4% | ||
| Q2 24 | -28.1% | 4.3% | ||
| Q1 24 | — | -14.9% |
| Q4 25 | 4.4% | 0.2% | ||
| Q3 25 | 2.8% | 0.5% | ||
| Q2 25 | 2.8% | 0.1% | ||
| Q1 25 | 3.0% | 0.1% | ||
| Q4 24 | 2.3% | 0.1% | ||
| Q3 24 | 0.5% | 0.6% | ||
| Q2 24 | 1.3% | 1.2% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | 242.00× | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
TACT
Segment breakdown not available.
